血管靶向光动力疗法与血卟啉单甲醚光动力疗法治疗微静脉畸形临床对比<br />研究<br />-《中国美容医学》

文章信息/Info

Title:: Clinical Comparative Study between Vascular Targeted Photodynamic Therapy
and Hematoporphyrin Monomethyl Ether Photodynamic Therapy in the Treatment of
Patients with Microvenous Malformation

Author(s):: ZHANG Mei1; LIU Yan-jun2; MENG Qing-hua1; ZHANG Wan3; HAN Xiao-yang1

Keywords:: Key words:V-PDT; HMME-PDT; microvenous malformation; effi cacy; adverse reactions; pain

摘要:: [摘要]目的：比较血管靶向光动力疗法（V-PDT）与血卟啉单甲醚光动力疗法（HMME-PDT）治疗微静脉畸形（原称鲜红斑
痣）的临床疗效。方法：选取2017年6月-2018年11月在笔者医院皮肤科就诊的42例微静脉畸形患者，根据治疗方法不同将所
有患者分为V-PDT组（20例）和HMME-PDT组（22例），V-PDT组患者给予V-PDT治疗，HMME-PDT组患者给予HMME-PDT治疗。观
察并比较两组的有效率、不良反应发生情况以及疼痛评分。结果：HMME-PDT组有效率95.45%，显著高于V-PDT组的70.00%，两
组有效率比较，差异具有统计学意义（P ＜0.05）。HMME-PDT组不良反应发生率9.09%，显著低于V-PDT组的40.00%，且差异具有
统计学意义（P ＜0.05）。HMME-PDT组手术疼痛评分显著低于V-PDT组，且差异具有统计学意义（P ＜0.05）。结论：在微静脉
畸形患者的治疗过程中，采用HMME-PDT进行治疗，临床疗效更加显著，可显著控制不良反应发生率，值得临床推广应用。

Abstract:: Abstract: Objective To compare the clinical efficacy between vascular targeted photodynamic therapy (V-PDT) and
hematoporphyrin monomethyl photodynamic therapy (HMME-PDT) in the treatment of patients with port wine stain (PWS).
Methods 42 patients with PWS were selected from June 2017 to November 2018. According to different treatment methods,
all patients were divided into the V-PDT group (20 cases) and the HMME-PDT group (22 cases). The V-PDT group was treated
with V-PDT, and the HMME-PDT group was treated with HMME-PDT. The effi cacy, adverse reactions and scores of pain in
the two groups were observed and compared. Results The effective rate in the HMME-PDT group (95.45%) was signifi cantly
higher than that in the V-PDT group (70.00%),with statistical difference (P ＜0.05). The incidence of adverse reactions in the
HMME-PDT group (9.09%) was significantly lower than that in the V-PDT group (40.00%) and with statistical difference
(P ＜0.05). The score of pain in the HMME-PDT group was significantly lower than that in the V-PDT group (P ＜0.05).
Conclusion HMME-PDT is more effective in the treatment of patients with PWS. It can signifi cantly control the incidence of
adverse reactions and is worthy of clinical promotion and application.